Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 2.

Slides:



Advertisements
Similar presentations
The Value of Medication Therapy Management Services.
Advertisements

Organization of Diabetes Care Chapter 6 Maureen Clement, Betty Harvey, Doreen M Rabi, Robert S Roscoe, Diana Sherifali Canadian Diabetes Association 2013.
Disease State Management The Pharmacist’s Role
The Value of Medication Therapy Management Services.
The Value of Medication Therapy Management Services
99.98% of the time patients are on their own “The diabetes self-management regimen is one of the most challenging of any for chronic illness.” 0.02% of.
Innovative Pharmacy Services Jann B. Skelton, RPh, MBA Vice President of Operations MEDICA.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
It’s A Success! Achieving Cost-Effective Disease Management in CHF Sherry Shults, RN BSN CIO South Carolina Heart Center.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Integrated Physical & Behavioral Health
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Objectives To understand: The concept of pharmaceutical care. MTM Chapter 3 required reading.
PPF- Atlantic Summit on Healthcare and Drug Cost Sustainability Perry Eisenschmid CEO, Canadian Pharmacists Association October 30, 2014.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
The Value of Medication Therapy Management Services.
1 Adding Value to Healthcare Management: Patient Self-Management: Diabetes MICHPHA September 20, 2007 Brooke Bliss, R.Ph. Clinical Pharmacy Consultant.
The Value of Medication Therapy Management Services.
LDL Program Medical Management Philip E. Johnston, Pharm.D.
Clinical Pharmacy Part 2
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
Healthy Heart Initiative and the Role of the Pharmacist Alexis Beyer, PharmD, NCPS Cherokee Indian Hospital Healthy Heart Pharmacist.
EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE Authors Institutions Authors: Silvia Martínez-Valverde MSc 1, Hortensia.
LOCKTON DUNNING BENEFITS UNIVERSITY OF ALASKA 2ND QTR FY13 UTILIZATION REVIEW 7/1/2012 TO 12/31/2012.
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
/ 201 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine Principles of Family Medicine Chronic Disease Management Dr.
What Does Research Tell Us? Care Manager Roles in Depression Care.
The Value of Medication Therapy Management Services.
Lowering Employer Healthcare Costs While Increasing Employee Engagement! Presented by: Flip Steinour, Director, Human Resources.
Multidisciplinary Diabetes Team Activities in a 196 Bed Community Hospital Robin Southwood, Pharm.D, CDE and Beth Melvin, RD, MS, CDE.
Emanuel Medical Center Case Management By: Deadre Hadden, RN.
Terry McInnis, MD MPH President- Blue Thorn, Inc - Mobile Co-Chair- Center for.
Use of EHR & Quality Based on Zhou, et al. The Relationship between Electronic Health Record Use and Quality of Care over Time. J Am Med Inform Assoc.
Transforming Care in Patient Centered Medical Home and Accountable Care Organization Hae Mi Choe, PharmD Director, Pharmacy Innovations & Partnerships.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
Pharmacy Health Information Technology Collaborative Presenter: Shelly Spiro RPh, FASCP Pharmacy HIT Collaborative, Executive Director.
Health Care, Education and Research Date: Oct 11, 2016 An Overview of the Efficacy of Delivering DSME and Group- Based DSME via Telehealth Barb Holloway,
Familial Hypercholesterolemia Foundation Patient Engagement and the Assessment of Value Cat Davis Ahmed Director of Outreach.
Medication therapy management
Effects of Case Management on Frequent
Healthstat Employee Clinic
Primary Care: Improving Access in Alberta
Has a regular source of care
Physical Health and People with a Severe Mental Illness
Cheryl Schraeder, RN, PhD, FAAN Health Systems Research Center
CONTROLLING THE COSTS OF HEMOPHILIA
Optimal Blood Glucose Monitoring
Cardiometabolic Health for Adult Diabetics Living in Beijing China
Telepsychiatry: Cost Effective Solution to Integrated Care
Clinical Pharmacy II.
John Peter Smith FMRP, Fort Worth, Texas
Diabetes Health Status Report
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Section 9: Continuum of care: Summary and timeline
Focus on Quality Webinar July 2018 Indiana Quality Improvement Network
Rational Order of Laboratory Tests in Cardiovascular Diseases
Pharmaceutical care planning 2 Ola Ali Nassr
Families USA Health Action 2019 Washington DC January 25, 2019
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.
Goals & Guidelines A summary of international guidelines for CHD
CROATIAN HEALTH INSURANCE FUND
Associate professor Mark Morgan Bond University
Section 6: Update on lipid treatment guidelines
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 2

Approaches for Cost Containment and Income Generation in Managing Patients With Diabetes and Dyslipidemia

Patients With Diabetes and Dyslipidemia Respond to Collaborative Care Patient Physician Allied Health Professionals (RNs, RPhs, RDs, psychologists) Patient Family & Peers Good chronic care requires a “prepared, proactive practice team interacting with an informed, activated patient” Bodenheimer T. JAMA. 2007;298(17):

Disease Management Programs Improve HEDIS Measures A1C Uncontrolled A1C Eye Patients, % P= P values controlled for age, sex, presence of pharmacy, enrollment duration, and insurance type. Sidorov J, et al. Diabetes Care. 2002;25(4): Patients not enrolled in program (n=3, 681) Patients enrolled in program (n=3,118) Testing Lipids Renal Screening P=0.0001

Disease Management Programs Reduce Spending in Patients With Diabetes Admissions Days ER Visits Primary Care Office Visits Paid Charges Mean, per member per month, $ Mean, per member Per year P< P=0.026 P=0.003 P=0.128 P=0.001 Monthly Paid Charges Healthcare Utilization P values controlled for age, sex, presence of pharmacy, enrollment duration, and insurance type. Sidorov J, et al. Diabetes Care. 2002;25(4): Patients enrolled in program (n=3,118) Patients not enrolled in program (n=3,681) Inpatient

Encourage Appropriate Lipid Management  Measures are needed to overcome clinical inertia and encourage appropriate and timely LDL-C management  25% of patients not receiving LDL-C lowering therapy had levels higher than recommended threshold for initiation of drug therapy a  30% of treated patients had LDL-C levels above recommended values a Mean (SD) No drug therapyDrug therapy Initial1 YearInitial1 Year Total cholesterol208 (47)210 (49)247 (55)219 (53) LDL-C138 (43)137 (45)174 (50) b 145 (45) b HDL-C48 (16)50 (17)47 (13)50 (12) Triglycerides141 (69)140 (76)164 (71)146 (69) Erdman DM, et al. Diabetes Care. 2002;25(1):9-15. a Study was conducted when NCEP II guidelines were in effect b At 1-year LDL-C was significantly decreased with drug therapy from initial (P<0.001)

Develop Strategies to Team Specialist Nurses With Diabetes Clinics  Nurse interventions included –Visits every 4 to 6 weeks –Patient education on disease, lifestyle factors, behavior changes, drug therapy, and treatment goals –Individualized action plan –Protocol-based medication adjustments  Specialist nurses-led clinics managed hyperlipidemia effectively when added to usual diabetes clinic care  32% more patients achieved cholesterol goals in the intervention arm New JP, et al. Diabetes Care. 2003;26(8): P= Percentage of patients achieving lipid goals

Nurse Care Management Improves Diabetes and Dyslipidemia Care Taylor CB, et al. Diabetes Care. 2003;26: Usual care (n=66) Intervention with nurse care manager (n=61) Change at 1 Year TC, mg/dL LDL, mg/dL HDL, mg/dL Triglycerides, mg/dL A1C, % P=0.01 P=0.02

Pharmacist-Directed Care in Diabetes: The Asheville Project Cranor CW, et al. J Am Pharm Assoc. 2003;4(2)3: Study Design Longitudinal, pre-post cohort-with-comparison group study PatientsPatients with diabetes covered by self-insured employers’ health plans (N=194 met inclusion criteria) InterventionEducation by certified diabetes educators Follow-up with community pharmacist with scheduled consultations, clinical assessment, goal setting, and monitoring Lipid management was key component of intervention Patients referred to diabetes education center or physician as needed Patients followed up to 5 years Outcome Measures Changes in A1C, LDL-C, HDL-C, and diabetes-related and total medical utilization and costs over time

Pharmacist-Directed Care Improves A1C, LDL-C, and HDL-C A1C LDL HDL Patients With Lab Values in Optimal Range*, % Follow-up Visit † Cranor CW, et al. J Am Pharm Assoc. 2003;43(2): *Optimal ranges defined as A1C 55 mg/dL (women) and >45 mg/dL (women). † Follow-up periods defined as 6-month intervals following baseline.

Pharmacist-Directed Care Improves Economic Outcomes in Patients With Diabetes Cranor CW, et al. J Am Pharm Assoc. 2003;43(2): Rx claims Insurance claims Follow-up Year Mean Cost Per Patient Per Year (US $2001)

Pharmacist-Directed Care Reduces Sick Time in Diabetes Sick Time per Patient per Year, Days (mean) Follow-Up Year Cranor CW, et al. J Am Pharm Assoc. 2003;43(2): Employer estimated increased productivity to be increased by $18,000 per year